The Effect of Cognitive-Based Neuromuscular Exercises on Reaction Time, Joint Position Sense, Proprioceptive Force Sense and Balance in Individuals Who Had Anterior Cruciate Ligament Surgery
Launched by ERTUĞRUL DEMIRDEL · Dec 24, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Anterior Cruciate Ligament (ACL) injuries are among the most common knee injuries, occurring due to both contact and non-contact mechanisms, such as sudden deceleration, changes in direction, or landing after jumping, and leading to disruptions in knee stability and biomechanics. In the United States, it is estimated that there are between 100,000 and 200,000 cases annually, while the global incidence of ACL ruptures approaches 2 million cases per year. Treatment for ACL injuries can be either conservative or surgical. Conservative treatment is considered a viable option for specific popula...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Having sustained a unilateral isolated anterior cruciate ligament injury,
- • Having undergone anterior cruciate ligament reconstruction using a hamstring graft by a surgeon at least 8 weeks ago,
- • Having completed the early phase of the postoperative criterion-based rehabilitation protocol and met the criteria for progression to the intermediate phase of the rehabilitation program (1- pain between 0-2 on the numeric pain scale, 2- no effusion in the knee, 3- no limitation in passive knee extension, 4- passive knee flexion of at least 120°, 5- full quadriceps activation (patient able to perform 10 repetitions of a single-leg raise exercise), and 6- normalized gait pattern without assistance).
- Exclusion Criteria:
- • Having a partial ACL tear,
- • Having sustained bilateral ACL injuries,
- • Having additional injuries accompanying the ACL injury,
- • Having undergone ACL revision surgery,
- • Having a history of complex knee surgery,
- • Having any neurological, orthopedic, or systemic disease that may contraindicate exercise.
About Ertuğrul Demirdel
Ertuğrul Demirdel is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and enhancing patient care. With a focus on innovative therapies and rigorous scientific methodologies, Demirdel oversees the design, implementation, and management of clinical trials across various therapeutic areas. His expertise in regulatory compliance and patient safety ensures that all trials are conducted with the highest ethical standards, fostering collaboration among researchers, healthcare professionals, and stakeholders. Through his leadership, Demirdel aims to contribute significantly to the development of effective treatments and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Antalya, , Turkey
Patients applied
Trial Officials
Ertugrul Demirdel, Associate professor
Study Director
Ankara Yildirim Beyazıt University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported